Publications by authors named "Recai Turkoglu"

Claim this Profile
S
Short and Long-Term Effects of Intravenous Methylprednisolone and Plasma Exchange Combination in NMOSD Attacks.
Duygu Özkan Yaşargün, Ayça Simay Ersöz, Recai Türkoğlu, Erdem Tüzün

Noro Psikiyatr Ars· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.
Jodie I Roberts, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Recai Turkoglu

J Neurol Neurosurg Psychiatry· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis.
Ruziye Erol Yildiz, Ece Akbayir, Tuğçe Kizilay, Ayça Simay Ersöz, Duygu Özkan Yaşargün

Turk J Med Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Recai Turkoglu

JAMA Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis.
Ece Akbayir, Tugce Kizilay, Ruziye Erol, Duygu Ozkan-Yasargun, Erdem Tuzun, Recai Turkoglu

In Vivo· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.
Pakeeran Siriratnam, Saif Huda, Anneke Van der Walt, Paul Sanfilippo, Sifat Sharmin, Recai Turkoglu

J Neurol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.
Pakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, Sifat Sharmin, Yi Chao Foong, Recai Turkoglu

J Neurol Neurosurg Psychiatry· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Simona Toscano, Tim Spelman, Serkan Ozakbas, Raed Alroughani, Clara G Chisari, Recai Turkoglu

Neurotherapeutics· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seronegative NMOSD patients display distinctive peripheral blood T-cell subset frequencies.
Elif Sanli, Zerrin Karaaslan, Vuslat Yilmaz, Tuncay Gunduz, Murat Kurtuncu, Recai Turkoglu

Clin Exp Immunol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiating multiple sclerosis with predominant spinal cord and optic nerve involvement from other autoimmune demyelinating diseases using B cell immunophenotyping and gene expression profiling.
Vuslat Yilmaz, Zerrin Karaaslan, Elif Sanli, Hande Yuceer-Korkmaz, Canan Aysel Ulusoy, Recai Turkoglu

Mult Scler Relat Disord· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
Pakeeran Siriratnam, Saif Huda, Anneke Van Der Walt, Paul G Sanfilippo, Sifat Sharmin, Recai Turkoglu

Neurology· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Wei Z Yeh, Anneke Van Der Walt, Olga G Skibina, Tomas Kalincik, Raed Alroughani, Recai Turkoglu

Neurol Neuroimmunol Neuroinflamm· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive Dysfunction in Multiple Sclerosis Patients with Hippocampal Antibodies.
Erdil Arsoy, Hande Yüceer, Beyzanur Yalçın, Sedat Günbek, Melike Tezel

Noro Psikiyatr Ars· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study.
Tuğçe Kızılay, Ece Akbayir, Ruziye Erol, Ayça Simay Demir, Duygu Özkan Yaşargün, Recai Turkoglu

Eur Neurol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Sifat Sharmin, Izanne Roos, Steve Simpson-Yap, Charles Malpas, Marina M Sánchez, Recai Turkoglu

Brain· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chloride intracellular channel protein-1 (CLIC1) antibody in multiple sclerosis patients with predominant optic nerve and spinal cord involvement.
Zerrin Karaaslan, Büşra Şengül-Yediel, Hande Yüceer-Korkmaz, Elif Şanlı, Duygu Gezen-Ak

Mult Scler Relat Disord· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice.
Gizem Koral, Canan Ulusoy, Judith Cossins, Konstantinos Lazaridis, Recai Türkoğlu

J Neuroimmunol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disability accrual in primary and secondary progressive multiple sclerosis.
Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B Malpas, Ibrahima Diouf, Recai Turkoglu

J Neurol Neurosurg Psychiatry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demyelinating Inflammatory Disorders of the Central Nervous System in the Era of COVID-19: Cases with Mild Infectious Symptoms.
Duygu Özkan Yaşargün, Recai Türkoğlu, Erdem Tüzün

Noro Psikiyatr Ars· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S Freedman, Harold Atkins, Recai Turkoglu

JAMA Neurol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Recai Turkoglu

Mult Scler· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder.
Zerrin Karaaslan, Vuslat Yilmaz, Hande Yuceer, Elif Sanli, Halil Ibrahim Akcay, Recai Turkoglu

North Clin Istanb· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.
Murat Terzi, Elif Merve Helvacı, Sedat Şen, Cavit Boz, Vedat Çilingir

Noro Psikiyatr Ars· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).
Meryem Aslı Tuncer, Murat Kürtüncü, Murat Terzi, Uğur Uygunoğlu, Cansu Göncüoğlu

Turk J Med Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.
Murat Terzi, Elif Merve Helvacı, Sedat Şen, Cavit Boz, Vedat Çilingir

Noro Psikiyatr Ars· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis